Nasal continuous positive airway pressure (CPAP) versus bi-level nasal CPAP in preterm babies with respiratory distress syndrome: a randomised control trial
- Gianluca Lista1,
- Francesca Castoldi1,
- Paola Fontana1,
- Irene Daniele1,
- Francesco Cavigioli1,
- Samantha Rossi1,
- Diego Mancuso3,
- Roberta Reali2
- 1NICU, Children's Hospital, Via Castelvetro, Milan, Italy
- 2Laboratory, ‘V.Buzzi’ Children's Hospital ICP, Milan, Italy
- 3Department of Statistics, Catholic University, Milan, Italy
- Correspondence to Gianluca Lista, NICU, ‘V.Buzzi’ Children's Hospital, Via Castelvetro, 32 20154 Milan, Italy;
- Accepted 27 October 2009
- Published Online First 29 November 2009
Objective To evaluate the clinical course, respiratory outcomes and markers of inflammation in preterm infants with moderate respiratory distress syndrome (RDS) assigned from birth to nasal continuous positive airway pressure (NCPAP) or bi-level NCPAP.
Methods A total of 40 infants with a gestational age (GA) of 28–34 weeks (<35 weeks' GA), affected by moderate RDS, were considered eligible and were randomised to NCPAP (group A; n=20, CPAP level=6 cm H2O) or to bi-level NCPAP (group B; n=20, lower CPAP level=4.5 cm H2O, higher CPAP level=8 cm H2O), provided with variable flow devices. Inflammatory response was the primary outcome; serum cytokines were measured on days 1 and 7 of life. Length of ventilation, oxygen dependency, need for intubation and occurrence of air leaks were considered as secondary outcomes.
Results Infants showed similar characteristics at birth (group A vs group B: GA 30.3±2 vs 30.2±2 weeks, birth weight 1429±545 vs 1411±560 g) and showed similar serum cytokine levels at all times. Group A underwent longer respiratory support (6.2±2 days vs 3.8±1 days, p=0.025), longer O2 dependency (13.8±8 days vs 6.5±4 days, p=0.027) and was discharged later (GA at discharge 36.7±2.5 weeks vs 35.6±1.2 weeks, p=0.02). All infants survived. No bronchopulmonary dysplasia (BPD) or neurological disorders occurred.
Conclusions Bi-level NCPAP was associated with better respiratory outcomes versus NCPAP, and allowed earlier discharge, inducing the same changes in the cytokine levels. It was found to be well tolerated and safe in the study population.
Competing interests None.
Ethics approval This study was conducted with the approval of the V.Buzzi Children's Hospital Ethics Committee.
Provenance and peer review Not commissioned; externally peer reviewed.
Patient consent Parental consent obtained.